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Strategies for the Detection of Atrial Fibrillation Recurrence
Insights From 647 Continuously Monitored Patients and Implications for
Monitoring After Therapeutic Interventions
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Derek R. Robinson, MA, MSc, DPhil, CStat; Hans-Hinrich Sievers, MD; Thorsten Hanke, MD
Background—Intermittent rhythm monitoring (IRM) to detect atrial fibrillation (AF) recurrence is employed to evaluate
the success of therapeutic interventions. In a large population of patients with continuous monitoring (CM), we
investigated the sensitivity of various frequencies and durations of IRM strategies on the detection of AF recurrence,
the dynamics behind AF recurrence detection, and we describe measures to evaluate temporal AF recurrence.
Methods and Results—Rhythm histories of 647 patients (mean AF burden, 0.120.22; median, 0.014; 687 patient-years)
with implantable CM devices were reconstructed and analyzed. With the use of computationally intensive simulation,
the sensitivity of IRM of various frequencies and durations on the identification of AF recurrence was evaluated.
Prolonged-duration IRM was superior to shorter IRM (P0.0001). However, even with aggressive IRM strategies, AF
recurrence was not detected in a great proportion of patients. The temporal AF burden aggregation (AF density) was
directly related to IRM sensitivity (P0.0001). Even at similar AF burdens, patients with high-density AF required
higher-frequency or prolonged-duration IRM to achieve the same sensitivity as in low-density AF (P0.0001). Patients
with high-density, low-burden AF benefit the most from CM for detection of AF recurrence.
Conclusions—IRM follow-up is significantly inferior to CM. IRM strategies will not identify AF recurrence in a great
proportion of patients at risk. Temporal AF characteristics play a significant role in AF recurrence detection with the
use of IRM. For the scientific, evidence-based evaluation of AF treatments, CM should be strongly recommended.
Prospective studies are required to evaluate whether CM to guide clinical management can also improve patient
outcomes.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00806689.
(Circulation. 2012;126:806-814.)
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Detection of atrial fibrillation (AF) recurrence after ther-apeutic interventions has until now been based primarily
on the results of intermittent (“snapshot”) rhythm monitoring
(IRM). This approach has significant limitations in terms of
sensitivity because the monitoring period of these examina-
tions is limited; however, the results of these examinations
are used to draw inferences on the success of ablation
procedures or pharmacological strategies. It has been shown
that reliance on symptoms or office ECGs overestimates the
success rate of the ablation procedures and will misclassify
patients who have recurrence of paroxysmal AF as being in
sinus rhythm.1–4 The current consensus on AF monitoring
recommends at least two 24-hour Holter monitor (HM)
examinations annually for the detection of AF recurrence
after ablation procedures,5–7 which, however, has also been
shown to underdetect AF recurrence and thus overestimate
procedural success.1,8 Reliable and accurate detection of AF
recurrence is thus of special importance for the evaluation of
pharmacological or ablation therapies as well as when deci-
sions on changes in anticoagulation or antiarrhythmic therapy
are to be made.
Editorial see p 791
Clinical Perspective on p 814
With the introduction of implantable, leadless rhythm
recorders, continuous monitoring (CM) has been proposed
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recently for more accurate detection of AF recurrence after
ablation procedures or novel pharmacological strategies.9 As
expected, the sensitivity of these diagnostic modalities is
close to 100% and, as such, is much superior to that of the
currently employed 24-hour HM strategies.8,10 However, the
implantation of a CM device in all patients may seem
unrealistic. This led to the belief that intensifying noninvasive
IRM either with greater frequency or with longer duration (7-
or 30-day monitoring) or both may lead to better and more
reliable detection of AF recurrence.1,11,12
Recently, data from CM patients have been used to
correlate the recurrence of AF with the risk for thromboem-
bolic complications.13–16 The advance of this technology has
not only provided better insight into the rhythm evaluation of
these patients but has also initiated a change of mentality
regarding AF from a qualitative (“yes/no”) to a quantitative
(amount of AF) approach. The AF burden, defined as the
proportion of the total monitored time a patient is in AF, has
been utilized in evaluating the risk for thromboembolism in
patients with AF.13–15 However, even these measures present
a rather static approach in the evaluation of the dynamic
incidence of AF recurrence, partially ignoring the temporal
dispersion or temporal aggregation of the AF episodes and
AF burden.
The aim of the present study was 2-fold: (1) to identify the
sensitivity of IRM strategies of various frequencies and
durations on the accurate detection of AF recurrence with the
use of data collected from patients with heart rhythm CM
devices and (2) to investigate the dynamics behind AF
recurrence detection and propose measures to evaluate the
temporal pattern of AF recurrence.
Methods
Data acquired from 647 patients monitored with a CM device
(Reveal XT 9529, n73; AT500 pacemaker, n574; Medtronic, Inc,
Minneapolis, MN) were analyzed. Demographics and patient char-
acteristics are summarized in Table 1. All patients provided informed
consent for the data collection and use, and the study was approved
by the local ethics committee.
With the use of data from the CM device, all AF episodes were
examined. Isolated AF episodes of 5 minutes duration that could
present artifacts were disregarded, and patients with no documented
AF episode were regarded as AF free (n174). The complete rhythm
history of every patient was reconstructed (Figure 1). Thereafter, we
calculated the probability of successful identification of AF recur-
rence by IRM of various durations (eg, 24 hours and 7, 14, and 30
days) and frequencies for every patient. Computationally intensive
simulation was employed to simulate in every patient all possible
IRM strategies of various durations and frequencies to draw infer-
ences on the sensitivity of the monitoring strategy and burden
characteristics of the patients being monitored. Sensitivity was
defined as the proportion of patients correctly identified as having
AF recurrence with the simulated IRM strategy to the true number of
patients having AF recurrence (identified from CM). AF burden was
defined as the proportion of the time in AF in relation to the total
monitored time. The simulation trials were performed as follows:
After reconstructing the rhythm history of every patient j, monitored
for a total of g days, we defined the sample space kj{1, 2, …,
g–k1} to be the set of possible days that a k-day intermittent
monitoring could be started (for k1, 2, 7, 14, and 30). A k-day
monitoring starting on day i  kj therefore included the following
associated monitored days: i, i1, …, ik–1. To simulate n
independent k-day monitorings of patient j, n elements were selected
at random from kj, except that elements were rejected if their
monitored days intersected with the monitored days of previously
selected elements. AF was deemed to have been successfully
identified if it was observed in at least 1 of the n sets of monitored
days. This was performed for all patients of the study population, for
monitoring durations of k1, 2, 7, 14, and 30 days, and for strategies
Table 1. Demographics of the Patient Population
Total %
Male 376 58.1
Age, meanSD, y 68.912.3
Follow-up, meanSD, range, y 1.10.4, 0.1–3.7
History of atrial arrhythmia
Atrial tachycardia 114 17.6
Atrial flutter 176 27.2
Paroxysmal AF 475 73.4
Persistent AF 32 4.9
Long-lasting persistent AF 35 5.4
History of cardioversion 18 2.8
Cardiovascular history
Ischemic heart disease 99 15.3
Coronary artery disease 220 34.0
Cardiomyopathy 64 9.9
Hypertension 405 62.6
History of ablation for AF
Cox/Maze III procedure 17 2.6
Left sided only 53 8.2
AV node ablation 28 4.3
Other 71 11.0
History of cardiac surgery
CABG 113 17.5
MVR 45 7.0
AVR 41 6.3
TVR 7 1.1
Ascending aorta replacement 9 1.4
PVR 1 0.2
NYHA class
I 331 51.2
II 234 36.2
III 67 10.4
IV 3 0.5
Pacing indication
AV block 85 13.1
Sinus node dysfunction 397 61.4
Other 41 6.3
Arrhythmia-related medication
Class I 89 13.8
Class III 251 38.8
-blocker 212 32.8
Calcium channel blocker 56 8.7
Digoxin 144 22.3
AF indicates atrial fibrillation; AV, atrioventricular; CABG, coronary artery
bypass grafting; MVR, mitral valve replacement/repair; AVR, aortic valve
replacement/repair; TVR, tricuspid valve replacement/repair; PVR, pulmonary
valve replacement; and NYHA, New York Heart Association.
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of n1, 2, 3, …, 12 monitorings. The simulations were performed
enough times (50 000) to allow stabilization of the inferred
parameter. All simulated IRM was of the continuous recording type.
Randomization tests were used to compare sensitivities of prolonged
IRM strategies with shorter IRM strategies and to compare patients
with high and low AF densities. The P values of 2-sided tests are
reported.
Using computationally intensive simulation, we sought to evaluate
the inferences that can be drawn from a series of negative IRM on the
patients’ AF burden. Upper 90% confidence intervals for the AF
burden of patients with a series of negative examinations for a given
IRM strategy were found by performing Monte Carlo simulations of
the strategy and evaluating the 90th percentile of AF burden among
those patients with a series of negative examinations in their
simulated monitorings.
With the complete rhythm history of every patient reconstructed,
we evaluated measures to describe the AF recurrence and burden
development over time, taking into consideration the temporal
aggregation of the episodes and the temporal dispersion of the AF
burden over the monitored period. For each patient, the course of the
AF burden development over time throughout the monitored period
was analyzed, and the minimum monitored time required for the
development of each proportion of the patient’s total observed AF
burden throughout the monitored period was calculated (blue or red
dotted line in Figure 2, bottom). For example, in Figure 2, patient C
develops 50% of his total burden in 11% of the monitored time
(black dot, patient C). Patient D, in contrast, required 40% of the
observation time to develop 50% of his burden (black dot, patient D)
as each day contributes less to the total burden because the AF
burden is spread over more days. The black diagonal line (Figure 2,
patients C and D) represents a hypothetical uniform AF burden
development (AF burden spread evenly throughout the monitoring
period). As a measure of temporal AF burden aggregation, the
cumulative deviation of the minimum monitored time required for
the development of each proportion of the patient’s total observed
AF burden throughout the monitored period from a hypothetical
uniform burden development (area between the actual [dotted line]
and the uniform burden development curves [solid diagonal], Figure
2) was calculated (blue or red highlighted area, Figure 2, bottom).
This measurement was then scaled relative to the maximum possible
burden aggregation for that specific patient’s burden (ie, the com-
plete burden as 1 continuous episode [“block of AF”]) to derive the
burden density, an index taking values between 0 (meaning AF
burden spread evenly over the observation time) and 1 (maximum
possible AF burden aggregation [ie, “1 block/episode of AF”]).
For the numeric evaluation of the patient’s AF density, we use the
following definitions: For a patient with a total AF burden b, denote
the minimum proportion of contiguous monitored time required for
the development of a proportion p of the patient’s total observed
burden b as F(p;b). The absolute cumulative deviation of the
patient’s actual burden development from the hypothetical uniform
burden development is evaluated as 0
1Fp;b	
pdp. When the
burden b occurs with maximum temporal aggregation (ie, the
complete burden as 1 continuous AF episode), the minimum time
required for the development of 100% of the total burden is
numerically equal to b, and the cumulative deviation from the
hypothetical uniform burden development is
1
b
2 . AF density is
numerically evaluated as follows:
AF density2*
0
1Fp;b	
pdp
1
b .
The detection probability gain of a CM versus an IRM strategy of
k duration [with a probability of AF detection in patient i of Pr(ki)]
was evaluated as
1
Prki	
Prki	 and depicts the increase in probability of
AF detection that CM offers in comparison to that of a random IRM
of k duration (k: 24 hours, 7 days, 14 days, 30 days). Linear
regression was used to determine whether AF burden and AF density
were independently associated with the probability gain. To restore
normality, the log of the probability gain was used as dependent
variable.
The Mann-Whitney test was used for comparing AF burdens
among patients with high and low density. All statistical analyses
and procedures were performed with R version 2.14.1 (R Develop-
ment Core Team; 2011; http://www.R-project.org/).
Results
Sensitivity of IRM
Quantitative AF characteristics are displayed in Figure 3.
Figure 4 displays the results for the sensitivity of random
24-hour and 7-, 14-, and 30-day monitorings at various
frequencies to detect AF recurrence for the entire patient
population. Prolonged IRM was significantly superior to
shorter IRM (P0.0001 for all comparisons). However, a
four 24-hour HM strategy had a sensitivity of only 52%, thus
failing to identify AF recurrence in almost half of the patients
with proven AF recurrence. Even with a theoretical strategy
of three 30-day HM tests (for a total monitoring duration of
90 days per year), the sensitivity did not exceed 82%, and
thus a nonnegligible proportion of patients with AF would be
misclassified (Figure 4). However, the increased sensitivity
offered by prolonged IRM durations comes at a cost of
disproportionate increase in the required monitored time to
achieve that level of sensitivity. For a sensitivity of 0.65, 30
days of monitoring would have been required with a 30-day
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Figure 1. Reconstruction of the rhythm history of patients A and
B. Both patients have similar atrial fibrillation (AF) burden (AF
burden for patient A0.22; AF burden for patient B0.21). The
vastly different temporal aggregation of the AF episodes and AF
burden in these patients is responsible for the different sensitivi-
ties of intermittent AF monitoring modalities in these patients.
For patient A, the probability of identification of AF recurrence
in a 24-hour and 30-day monitor is Pr(24h|A)0.23 and
Pr(30d|A)0.26. In this case, a random 30-day monitoring
increases the sensitivity by only 3% from that which random
24-hour Holter monitoring (HM) would provide. For patient B,
the respective probabilities are Pr(24h|B)1 and Pr(30d|B)1.
The numbers 1 and 2 denote the time points of 2 random
24-hour HM tests, whereas the numbers 3 and 4 denote the
time points of 2 random 30-day HM tests.
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HM strategy (one 30-day HM test), whereas for the same
sensitivity, 7 monitored days would have been required with
a 24-hour HM strategy (seven 24-hour HM tests) (Figure 4,
solid horizontal black line).
Inferences Drawn From a Series of Negative IRM
Using computationally intensive simulation, we sought to
evaluate the inferences that can be drawn from a series of
negative IRM on the patients’ AF burden. Although IRM
strategies cannot determine the precise AF burden, reliable
inferences can be obtained (for example, a patient with 4
negative random 30-day HM tests is highly unlikely to have
a burden of 80%). These probabilities were derived from
our patient population, taking into consideration not only the
amount of AF in each patient but also the temporal charac-
teristics of AF, and are displayed in Figure 5. A series of 4
negative random 30-day HM tests suggests with 90% confi-
dence that this patient’s AF burden is 17%. Similarly, 8
negative 24-hour HM tests would be required to achieve the
same level of confidence regarding the patient’s AF burden.
IRM of shorter duration requires a higher number of exami-
nations to achieve the same level of confidence as IRM of
longer durations (Figure 5).
Influence of AF Burden and AF Density on
Effectiveness on IRM
Using the reconstructed rhythm histories of our patients, we
attempted to evaluate the quantitative as well as temporal AF
characteristics that drive the sensitivity differences between
IRM of various durations and frequencies. Burden density
was directly related to the sensitivity of the different moni-
toring durations (Figure 6). Even with similar AF burdens
(burden of low-density group: mean, 0.120.11; median,
0.07; quartile 1, 0.01; quartile 3, 0.18; burden of high-density
group: mean, 0.130.14, median, 0.06; quartile 1, 0.01;
quartile 3, 0.19; P0.36), patients with low-density AF (AF
density 0.5) achieve higher sensitivities for AF recurrence
detection compared with patients with high-density AF (AF
density 0.5; P0.0001 for all comparisons of all monitor-
ing duration sensitivities [24-hour, 7-day, 14-day, 30-day
HM] between high- and low-density groups). In patients with
high-density AF, AF recurrence is much more difficult to
0 100 200 300
0
20
0
60
0
10
00
14
00
Patient C Patient D 
D
ai
ly 
m
in
 in
 A
F
AF Burden :  0.21 
AF Density:  0.99
Days since Implant
0 100 200 300
0
20
0
60
0
10
00
14
00
D
ai
ly 
m
in
 in
 A
F
AF Burden :  0.21 
AF Density:  0.05
Days since Implant
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Proportion of total monitored time
Pr
op
or
tio
n 
of
 to
ta
l b
u
rd
en
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Proportion of total monitored time
Pr
op
or
tio
n 
of
 to
ta
l b
u
rd
en
Figure 2. Two patients with the same atrial fibrilla-
tion (AF) burden but different burden aggregation
(patient C, high-density AF; patient D, low-density
AF). With the rhythm history reconstructed, the
course of the minimum monitored time required for
each burden proportion is plotted against the pro-
portion of the total burden (dotted line, patients C
and D, bottom). Patient C developed 50% of his
total burden in 11% of the monitored time (black
dot, patient C, bottom). Patient D, in contrast,
required 40% of the observation time to develop
50% of his burden (black dot, patient D, bottom)
as each day contributes less to the total burden
because the AF burden is spread over more days.
The black diagonal line (patients C and D, bottom)
represents a hypothetical uniform AF burden
development. The area between the actual (blue or
red dotted line) and the uniform hypothetical (solid
black diagonal) AF burden development is evalu-
ated as a measure of the temporal aggregation of
the AF burden (AF burden density).
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Figure 3. Histogram of the patients’ atrial fibrillation (AF) bur-
dens. A total of 174 patients with no documented AF episode
during the monitored time were excluded.
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capture with the use of IRM than in patients with low-density
AF, even at similar AF burdens.
The superiority of CM in comparison to IRM was found to
be significantly related to the AF burden and the AF density
(Table 2). When CM is compared with 24-hour HM, the
lower the AF burden and the higher the AF burden density,
the greater is the gain from CM for AF recurrence detection
(Figure 7, left). Patients with low-burden, high-density AF
profit the most from CM. When CM was compared with a
30-day HM strategy, the gain obtained with CM was also
found to be significantly related to the AF density and the AF
burden. The higher the AF density and the lower the AF
burden, the higher is the detection probability gain from the
CM strategy (Figure 7, right).
Discussion
This study provides insights into the sensitivity of various
monitoring strategies for the detection of AF recurrence with
the use of data from a large patient population monitored with
CM devices. Although 2 different monitoring devices were
employed, AF detection in both devices was similar. The aim
of our study was not to evaluate the AF detection process of
the devices, which has been extensively validated previ-
ously,10,17–19 but to evaluate the characteristics and dynamics
of AF recurrence detection after AF episode registration.
Although this patient population presents an inhomoge-
neous collection of patients being monitored continuously
with implantable devices, this gives us the opportunity to
observe the characteristics of a very wide range of AF burden
spectrum. The lower end of the AF burden spectrum is
predominantly occupied by patients implanted with a CM
device for monitoring after ablation procedures (mean AF
burden, 0.050.16; median, 0.002; quartile 1, 0.001; quartile
3, 0.01) or patients with paroxysmal, asymptomatic AF,
whereas the higher end of the spectrum is predominantly
occupied by patients implanted with a pacemaker device for
symptomatic bradyarrhythmia and long-lasting persistent AF.
This wide range of AF burden observed allowed us to
evaluate the sensitivity of the IRM strategies and evaluate the
AF burden dynamics over a wide range of AF burdens.
Judgment of Therapeutic Success Based on IRM
Our group and other groups have previously evaluated
sensitivity differences between IRM and CM by comparing
the information obtained from CM devices with actual IRM
performed in the same patients.1,4,8,11 However, these meth-
ods have limitations because the time point of the IRM plays
a major role in the evaluation of these methods. As depicted
in Figure 1, in patient A, a 24-hour HM test performed at time
point 1 will be negative and patient A will be regarded as “AF
free,” whereas the same examination performed some days
earlier at time point 2 would have identified AF recurrence.
The results of such studies comparing continuous versus
actual IRM are severely influenced by the choice of time
points when the IRM is performed. Because in most of these
studies only a limited number of IRM tests were compared
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Figure 4. The sensitivity of intermittent rhythm monitoring (IRM)
to detect atrial fibrillation (AF) recurrence as a function of moni-
toring frequency (number of random monitorings) and monitor-
ing duration (24 hours and 7, 14, and 30 days) in patients with
proven AF recurrence. Only patients with documented AF recur-
rence were included. Prolonged IRM was significantly superior
to shorter IRM (P0.0001 for all comparisons). However, a four
24-hour Holter monitoring (HM) strategy had a sensitivity of only
52%, thus failing to identify AF recurrence in almost half of the
patients with proven AF recurrence. The dotted horizontal line
represents the sensitivity of 0.5 (fair coin). To achieve a sensitiv-
ity of 0.65 (solid horizontal line), 30 days of monitoring would
have been required with a 30-day HM strategy (one 30-day HM
test). To achieve the same sensitivity, 7 monitored days would
have been required with a 24-hour HM strategy (seven 24-hour
HM tests). The total number of monitored days required at the
maximum frequency of each monitoring strategy is denoted.
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Figure 5. Inferences on atrial fibrillation (AF) burden drawn by
hypothetical negative intermittent rhythm monitoring (IRM)
examinations of the overall study population. For the study pop-
ulation, a series of 2 negative random 24-hour Holter monitor
(HM) tests imply with a confidence of 90% that the patient’s
burden is 32%. Similarly, a series of 4 negative random
30-day HM tests imply with a confidence of 90% a burden
of 17%. Eight negative series of 24-hour HM tests would
have been required to obtain the same level of AF burden
confidence.
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against CM, chance has an immeasurable effect on the results
of such studies, and any inferences drawn from these results
will be problematic. In the present study, the reconstruction
of the rhythm history of every patient allows us to evaluate
the true probability of AF recurrence detection of any random
IRM of any duration in every patient, and computationally
intensive simulation can draw inferences on the sensitivities
and success rates of IRM of any duration and frequency.
Figure 4 presents the results of this approach in our patient
collective, depicting the sensitivities of the 4 most common
IRM durations (24-hour and 7-, 14-, and 30-day HM) at
various monitoring frequencies. In our patient population, a
monitoring strategy with four 24-hour HM tests would have
a sensitivity of only 52%, thus failing to identify recurrence
of AF in almost half of these patients. This low sensitivity
becomes even more striking if one considers that the flipping
of a fair coin would have provided the same sensitivity for the
detection of AF recurrence in these patients. The direct
implication of these results is that the evaluation of pharma-
cological or interventional therapies when a 24-hour HM is
employed as a monitoring strategy should be interpreted
cautiously because a great proportion of patients will be
misclassified, AF recurrence will be underdiagnosed, and
therapeutic success will be overestimated. Similarly, a single,
random 30-day HM in our patient population will have a
sensitivity of 63%, and thus the evaluation of the success of
an ablation procedure with the use of a single, postinterven-
tional, 30-day HM would have a sensitivity of only 63%
(slightly better than the sensitivity the flipping of a fair coin
would provide). Even in the theoretical scenario of using
three 30-day HM tests (for a total of 90 monitored days per
year) would have a sensitivity of 82%; however, such a
strategy seems unrealistic because it has been shown that
complex or prolonged IRM strategies severely affect patient
compliance.7 To obtain the sensitivities of the various IRM
strategies presented in this report, a 100% patient compliance
is assumed; however, this is rarely the case in everyday
clinical practice because even short-duration IRMs pose a
significant compromise in the patients’ quality of life, and
this has been shown to lead to monitoring discontinuation.7,20
Roten et al20 recently showed that even with medium-
duration IRM (7-day HM), 42% of patients complained of
discomfort and skin irritation, whereas 16% discontinued the
monitoring because of this reason. On the other hand, the
implantation of leadless CM requires a minor surgical proce-
dure, and the device itself may carry a risk of infection or
patient discomfort. Prolonged IRM strategies not only have
reduced patient compliance but also offer diminished returns
in terms of sensitivity gained per monitored day. The latter
problem is depicted in Figure 4. To achieve the same
sensitivity (0.63; solid black horizontal line, Figure 4), 30
days of monitoring would have been required with a 30-day
HM strategy (one 30-day HM test) versus only 7 days of
monitoring with a 24-hour HM strategy (seven 24-hour HM
tests). This disproportionate increase in required monitoring
time to achieve a certain level of sensitivity between long-
and short-duration IRM would certainly have an impact on
patient compliance with aggressive IRM strategies.
If the AF burden temporal characteristics are also taken
into consideration (Figure 6), the detection of AF recurrence
in patients with high-density AF becomes even more prob-
lematic. In the case of patients with high AF burden densities,
a strategy of six 24-hour HM tests or one 30-day HM test
would have been needed to provide a sensitivity of 50%
(similar to that of a fair coin). In the low-density group, six
24-hour HM tests or one 30-day HM test would have
provided a sensitivity of 0.72 and 0.86, respectively. Thus,
patients with high-density AF require an even more aggres-
sive IRM strategy to detect AF recurrence and evaluate
results of therapeutic interventions. It becomes clear that with
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Figure 6. Sensitivity of various intermittent rhythm monitoring
durations at various frequencies in patients with high (0.5) and
low (0.5) atrial fibrillation (AF) burden density. Both high- and
low-density AF groups had similar AF burdens (burden of low-
density group: mean, 0.120.11; median, 0.07; quartile 1, 0.01;
quartile 3, 0.18; burden of high-density group: mean,
0.130.14; median, 0.06; quartile 1, 0.01; quartile 3, 0.19;
P0.36). Low-density AF patients achieve higher AF recurrence
detection sensitivity with less frequent monitoring than patients
with high-density AF. In patients with high-density AF (blocks of
AF), a significantly (P0.0001) higher monitoring frequency is
required to detect recurrence of AF. Only patients with docu-
mented AF recurrence were included. HM indicates Holter
monitoring.
Table 2. Linear Regression Analysis of Effect of Burden and
Burden Density on the Probability Gain of AF Recurrence
Detection of 30-Day and 24-Hour HM vs Continuous Monitoring
Factor Coefficient P
Gain in AF recurrence detection:
continuous vs 24-h HM
AF burden 
5.76 0.0001
AF burden density 2.61 0.0001
Gain in AF recurrence detection:
continuous vs 30-d HM
AF burden 
4.08 0.0001
AF burden density 4.84 0.0001
AF indicates atrial fibrillation; HM, Holter monitoring. To restore normality,
the log of the probability gain was used as dependent variable.
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intermittent monitoring altogether, a great part or even the
majority of patients will be misclassified, and therefore the
scientific evaluation of therapeutic interventions for AF
becomes problematic.
Semiquantitative Estimation of AF Burden Based
on Negative IRM
Although IRM may fail to detect AF recurrence in a great
proportion of patients and cannot provide the level of infor-
mation a CM strategy does, results of serial IRM may guide
patient management in a semiquantitative way when CM is
not possible because of either limited availability, patient
compliance, or cost considerations. Such an evaluation is
depicted in Figure 5. A series of negative IRM, although may
underestimate qualitative AF detection per se, can however
guide estimation of the potential AF burden level in patients
prone to AF recurrence such as patients after ablation
procedures, or patients on rhythm control strategies. In our
large population of CM patients, 4 random negative
24-hour HM tests indicate, with a confidence of 90%, an
AF burden of up to 23%. A higher number of serial
negative IRM tests or negative IRM tests of greater
duration can pinpoint the potential AF burden to lower
levels. However, it is important to note that even average
burdens that low have been shown to be a risk factor for
thromboembolic complications.13–16,21
AF Characteristics Influencing the Success of IRM
A major variable driving the sensitivity in detecting AF
recurrence is not only the AF burden but the dispersion of it
over time. AF density, as a measure of this dispersion, proved
to be a major factor that influences the sensitivity of IRM at
various frequencies and durations. Although patients A and B
of Figure 1 have very similar amounts of AF burden over the
same observation time, the probability of AF recurrence
detection is vastly different because of the different temporal
AF burden dispersion. In patient B (Figure 1), because of the
even dispersion of AF burden, prolonged-duration IRM
(30-day HM) is not superior to shorter-duration IRM (24-
hour HM), the probability of AF recurrence detection of both
IRM tests is 1, and the sensitivity of both strategies is 100%.
In patient A (Figure 1), however, because of the high AF
density, a random 30-day HM test offers only a negligible 3%
increase in probability of AF recurrence detection compared
with a random 24-hour HM test. In the whole patient cohort
(Figure 6), the AF density appears to have a major and
statistically significant influence on the sensitivity of AF
detection with the use of IRM strategies. In patients with
high-density AF, the probabilities of AF recurrence detection
and the sensitivities of IRM strategies are significantly
inferior to those of patients with same level of AF burden but
low AF density (Figure 6).
Implications for Clinical Outcomes, Patient
Management, and Current Knowledge
Although the level of AF burden has been shown to be a
significant risk factor for thromboembolic events,13–16 to the
best of our knowledge, no study has taken into consideration
the temporal characteristics of AF burden development. It is
conceivable that the temporal distribution of AF burden may
also play a role in the general thromboembolic risk that
patients with AF face. Patients A and B (Figure 1), although
spending the same time in AF, may have a different throm-
boembolic risk because of the different temporal distribution
of their AF burden. Larger studies are required to evaluate
this hypothesis, and prospective studies are required to
evaluate the clinical impact of the combined quantitative and
temporal AF characteristics on patient outcome.
The data presented may have some clinical implications.
The results of our study depict the major limitations of IRM
not only for management of patients but also for evaluation of
the results of pharmacological as well as interventional
therapies for AF. From a clinical perspective, accurate patient
management can only be obtained with confidence with CM.
From a scientific perspective, our evaluation until now of the
success of pharmacological and interventional procedures
based on IRM seems problematic in light of the results
presented in this study. The accurate evaluation of therapies
for AF in the era of evidence-based medicine mandates the
use of CM.
It is conceivable that the widespread use of CM or the
results from large studies of CM patients may require us to
reevaluate our definitions of success or failure of therapeutic
intervention for AF. It may very well be that the current
definition of success of a therapeutic intervention only in
terms of complete absence of AF recurrence might be
inadequate and that a quantitative approach to AF recurrence
may in the future require us to critically revisit our current
knowledge and reevaluate our therapeutic interventions and
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Figure 7. Gain in atrial fibrillation (AF) recurrence
detection when using continuous monitoring ver-
sus 24-hour Holter monitoring (HM) (left) or 30-day
HM (right) with respect to AF burden and burden
density. Continuous monitoring offers significantly
increased sensitivity in AF recurrence detection
with a lower AF burden and a higher AF density
(Table 2). The gain obtained with continuous moni-
toring diminishes at burdens 0.4. AF burden den-
sity has been categorized into 3 categories (high,
0.6–1; mid, 0.3–0.6; low, 0–0.3).
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strategies, our results, and our patient management decision-
making process. Whether the use of CM to guide clinical
management can also improve patient outcomes remains
uncertain at this point and must be investigated in large
randomized controlled prospective studies.
Limitations
This study was underpowered to investigate the clinical
impact of temporal AF characteristics on patient outcomes.
We believe that this should be the scope of large prospective
studies or registries of CM patients over sufficient follow-up
time. AF episodes of patients primarily implanted with a CM
device because of atrial tachycardia or atrial flutter have been
included in the analysis. In our experience, although patients
are typically classified in 1 distinct rhythm type (atrial flutter,
AF, or atrial tachycardia), CM reveals that these patients
actually tend to experience multiple types of atrial rhythms.
Although 2 different devices were employed in the popula-
tion of this study, previous studies have extensively investi-
gated the accuracy of AF detection of these devices (sensi-
tivity, 98%; specificity, 91%).10,17,18 Additionally, we
tried to manually inspect all available episodes and, in cases
of uncertainty or dispute, we discarded isolated, short (5
minutes) episodes that could represent artifacts.
Conclusion
Patient follow-up with either short- or long-duration IRM is
significantly inferior to CM for the detection of AF recur-
rence. IRM monitoring strategies will not identify AF recur-
rence in a great proportion of patients at risk. With short-
duration, low-frequency IRM strategies, chance has an
immeasurable effect on the evaluation of AF recurrence.
Thus, results of pharmacological or invasive interventions
evaluated with IRM should be considered with caution.
Temporal AF characteristics play a major role in AF recur-
rence detection with the use of IRM strategies and may
influence clinical parameters and outcomes in AF patients.
For the scientific, evidence-based evaluation of AF treat-
ments, CM should be strongly recommended.
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CLINICAL PERSPECTIVE
Patient follow-up with either short- or long-duration intermittent rhythm monitoring is significantly inferior to that with
continuous rhythm monitoring for the detection of atrial fibrillation (AF) recurrence. Intermittent rhythm monitoring
strategies fail to identify AF recurrence in a great proportion of patients at risk. Even with feasible, aggressive intermittent
monitoring strategies (such as quarterly 24-hour Holter monitoring), AF recurrence will not be identified in a significant
proportion of patients. Because of the low sensitivity of intermittent rhythm monitoring, the results of pharmacological or
invasive interventions for AF when evaluated with intermittent monitoring should be considered with caution because
chance has an immeasurable effect on the detection of AF recurrence, and thus a great proportion of patients will be
misclassified, AF recurrence will be underdiagnosed, and therapeutic success will be overestimated. Novel quantitative and
temporal AF characteristics (AF burden, AF density) play a major role in AF recurrence detection with the use of
intermittent monitoring strategies and may influence clinical parameters and outcomes in AF patients. For accurate patient
management, as well as for the scientific, evidence-based evaluation of AF treatments, continuous rhythm monitoring
should be strongly recommended.
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